Home > Oncology > ASCO 2020 > Lung Cancer > ES-SCLC: pembrolizumab KEYNOTE-604 data

ES-SCLC: pembrolizumab KEYNOTE-604 data

Presented By
Dr Charles M. Rudin, Memorial Sloan Kettering Cancer Center, USA
ASCO 2020
Phase 3, KEYNOTE-604
Data from the phase 3 KEYNOTE-604 trial showed that patients with extensive-stage small cell lung cancer (ES-SCLC) who received pembrolizumab with backbone chemotherapy etoposide/platinum (EP) compared with patients who received EP and placebo did not benefit from improved overall survival (OS). However, progression-free survival (PFS) rates did reach the threshold for significance. Dr Charles M. Rudin (Memorial Sloan Kettering Cancer Center, USA) presented the findings [1]. The KEYNOTE-604 study aimed to improve upon the efficacy of immunotherapy in newly diagnosed ES-SCLC with the combination of pembrolizumab and EP. The study randomised 453 patients to pembrolizumab 220 mg on day 1 plus EP 100 mg/m2 on days 1 and 2 and carboplatin AUC 5 on day 1 or cisplatin 75 mg/m2 on day 1 (n=228) or placebo, matc...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on